Millennium Pharmaceuticals to Acquire COR Therapeutics in $2.0 Billion Deal

Millennium Pharmaceuticals to Acquire COR Therapeutics in $2.0 Billion Deal

Firm News

On December 6, 2001, Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) announced that it had signed a definitive agreement to acquire COR Therapeutics, Inc. (Nasdaq: CORR) in a stock-for-stock exchange valued at $2.0 billion.

Millennium was advised by the following Hale and Dorr lawyers:

  • on corporate and securities matters, partners David Redlick, Jeff Stein and Jonathan Wolfman, junior partner Ken Lepage and associate Kris Spreen;
  • on intellectual property and licensing matters, partner Steven Singer, junior partner Michael Twomey and associates Jan Siok and Soojin Chung;
  • on tax matters, partner Rob Burke and associate Erika Buell;
  • on real estate matters, partner Keith Barnett;
  • on environmental matters, partner Rob Kirsch and associate Pat van der Voorn;
  • on employee benefits matters, partner Bill Schmidt; and
  • on immigration matters, partner Carolyn Fuchs.

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link. (The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.